Company · CIK 0001841387 · SIC 2836 — Biological Products, (No Diagnostic Substances) · Nasdaq
Candel Therapeutics, Inc. · CADL
Insider activity reported against this company. All insider holders · On EDGAR ↗
Reported at this company — common stock
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 SForm 4 → | Sep 11, 6:12 pm EDT | Paul Peter TakChief Executive Officer, Director | 280,245 | $11.28 | $3,160,783 | 113,321 | −71.2% | 10b5-1 |
| Sep 10, 2026 MForm 4 → | Sep 11, 6:12 pm EDT | Paul Peter TakChief Executive Officer, Director | 125,000 | $1.55 | $193,750 | 393,566 | — | 10b5-1 |
Reported at this company — derivatives (options, RSUs, warrants)
| Trade | Reported (ET) | Insider | Shares | Avg price | Total | Owned after | Δ stake | Flags |
|---|---|---|---|---|---|---|---|---|
| Sep 10, 2026 MForm 4 → | Sep 11, 6:12 pm EDT | Paul Peter TakChief Executive Officer, Director | 125,000 | — | — | 1,638,968 | — | 10b5-1 |
| Sep 8, 2026 AForm 4 → | Sep 10, 4:24 pm EDT | Martine ZimmermannDirector | 64,000 | — | — | 64,000 | — |